http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20180058716-A

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_09ad8b5b3bc0add056634855c0f0c720
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7048
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4409
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-438
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-165
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-498
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-435
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-495
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-498
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-435
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-438
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4409
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-495
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
filingDate 2016-10-06-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_04c0c35d0d92a6cf5a42f7a74710a5a7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a18dacde253a7f98c81dab1d8aa9c9ed
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f8fd5f35ae091217ab5891027a2c3fa5
publicationDate 2018-06-01-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber KR-20180058716-A
titleOfInvention Combination therapy to treat cancer
abstract There is provided a method for treating cancer in a patient by administering at least one antibiotic selected from the group consisting of cryptazin, rifabutin, and clarithromycin in combination with an aryladamantane compound. In one embodiment, the aryladamantane compound is [3- (4-chlorophenyl) -adamantane-1-carboxylic acid (pyridin-4-ylmethyl) amide], or a pharmaceutically acceptable salt thereof.
priorityDate 2015-10-06-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID15604015
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID421745324

Total number of triples: 32.